278 related articles for article (PubMed ID: 38673824)
1. The Complex Relationship between Mechanisms Underlying Inflammatory Bowel Disease, Its Treatment, and the Risk of Lymphomas: A Comprehensive Review.
Stasik K; Filip R
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673824
[TBL] [Abstract][Full Text] [Related]
2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
3. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.
Subramaniam K; D'Rozario J; Pavli P
J Gastroenterol Hepatol; 2013 Jan; 28(1):24-30. PubMed ID: 23094824
[TBL] [Abstract][Full Text] [Related]
4. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.
Kobayashi T; Uda A; Udagawa E; Hibi T
J Crohns Colitis; 2020 Jun; 14(5):617-623. PubMed ID: 31867632
[TBL] [Abstract][Full Text] [Related]
5. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
[TBL] [Abstract][Full Text] [Related]
8. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
Beaugerie L; Brousse N; Bouvier AM; Colombel JF; Lémann M; Cosnes J; Hébuterne X; Cortot A; Bouhnik Y; Gendre JP; Simon T; Maynadié M; Hermine O; Faivre J; Carrat F;
Lancet; 2009 Nov; 374(9701):1617-25. PubMed ID: 19837455
[TBL] [Abstract][Full Text] [Related]
9. Cancer and immunomodulators in inflammatory bowel diseases.
Biancone L; Onali S; Petruzziello C; Calabrese E; Pallone F
Inflamm Bowel Dis; 2015 Mar; 21(3):674-98. PubMed ID: 25545375
[TBL] [Abstract][Full Text] [Related]
10. Lymphoproliferative Disorders in Inflammatory Bowel Disease Patients: Is It the Drugs or the Disease.
Bernardes C; Russo P; Carvalho D; Saiote J; Ramos J
GE Port J Gastroenterol; 2018 Jun; 25(4):175-178. PubMed ID: 29998162
[TBL] [Abstract][Full Text] [Related]
11. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment.
Aithal GP; Mansfield JC
Aliment Pharmacol Ther; 2001 Aug; 15(8):1101-8. PubMed ID: 11472312
[TBL] [Abstract][Full Text] [Related]
12. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
Magro F; Peyrin-Biroulet L; Sokol H; Aldeger X; Costa A; Higgins PD; Joyce JC; Katsanos KH; Lopez A; de Xaxars TM; Toader E; Beaugerie L
J Crohns Colitis; 2014 Jan; 8(1):31-44. PubMed ID: 23721759
[TBL] [Abstract][Full Text] [Related]
13. Monitoring for Extra-Intestinal Cancers in IBD.
Sifuentes H; Kane S
Curr Gastroenterol Rep; 2015 Nov; 17(11):42. PubMed ID: 26364836
[TBL] [Abstract][Full Text] [Related]
14. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
15. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review.
Hashash JG; Elkins J; Lewis JD; Binion DG
Gastroenterology; 2024 Mar; 166(3):521-532. PubMed ID: 38276922
[TBL] [Abstract][Full Text] [Related]
16. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases.
Beaugerie L; Rahier JF; Kirchgesner J
Clin Gastroenterol Hepatol; 2020 May; 18(6):1324-1335.e2. PubMed ID: 32059920
[TBL] [Abstract][Full Text] [Related]
17. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis.
Yang C; Huang J; Huang X; Huang S; Cheng J; Liao W; Chen X; Wang X; Dai S
J Crohns Colitis; 2018 Aug; 12(9):1042-1052. PubMed ID: 29762681
[TBL] [Abstract][Full Text] [Related]
18. Previous cancer and/or lymphoma in patients with refractory IBD--con: anti-TNF or conventional immunosuppressive treatment.
Mantzaris GJ
Dig Dis; 2014; 32 Suppl 1():122-7. PubMed ID: 25531364
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment.
Bergamaschi G; Di Sabatino A; Albertini R; Ardizzone S; Biancheri P; Bonetti E; Cassinotti A; Cazzola P; Markopoulos K; Massari A; Rosti V; Porro GB; Corazza GR
Haematologica; 2010 Feb; 95(2):199-205. PubMed ID: 19815838
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series.
Phillips F; Verstockt B; Ribaldone DG; Guerra I; Teich N; Katsanos K; Filip R; Molner T; Karmiris K;
J Crohns Colitis; 2022 Mar; 16(3):500-505. PubMed ID: 34508639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
